Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | GRM5 | P41594 | 5/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.40 |
| ▸ | GCK | P35557 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114863 | 0.91 | GRM5 (0.42) | AAK1CTSSCTSKGRM5USP30 | |
| SCHEMBL4109054 | 0.86 | GRM5 (0.49) | AAK1CTSSCTSKGRM5SCN9A | |
| SCHEMBL2520163 | 0.86 | GRM5 (0.49) | AAK1CTSSCTSKGRM5SCN9A | |
| SCHEMBL2668369 | 0.83 | GRM5 (0.48) | GRM5GRM4GCK | |
| SCHEMBL4114950 | 0.82 | GRM5 (0.44) | GRM5GRM4GCK | |
| SCHEMBL2669321 | 0.79 | AAK1 (0.47) | AAK1CTSSCTSKGCK | |
| SCHEMBL4103721 | 0.78 | GRM5 (0.47) | AAK1GRM5SCN9A | |
| SCHEMBL2668370 | 0.78 | GCK (0.44) | GRM5USP30GRM4GCK | |
| SCHEMBL4102212 | 0.78 | GRM5 (0.46) | GRM5GRM4GCK | |
| SCHEMBL9072799 | 0.77 | CTSS (0.52) | AAK1CTSSCTSKUSP30GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173645-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173645-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | AAK1 189/4885CTSS 843/4885CTSK 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.